Lexipafant inhibits postsurgical adhesion formation

Journal of Surgical Research

Volumn 103, Issue 2, 2002, Pages 141-145

  Özgün, Hedef ^a   Çevikel, Mehmet Hakan ^a   Kozaci, Leyla Didem ^a   Sakarya, Serhan ^a  

^a ADNAN MENDERES UNIVERSITY   (Turkey)

Author keywords

Hydroxyproline; Lexipafant; Peritoneal adhesions; Wound healing

Indexed keywords

HYDROXYPROLINE; INTERLEUKIN 6; LEXIPAFANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL ANALYSIS; CONTROLLED STUDY; FEMALE; LAPAROTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SAMPLING; SKIN INCISION; UTERUS BLEEDING; UTERUS HORN;

EID: 0036353582     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.2002.6357     Document Type: Article

References (48)

1. Deperitonealization: Clinical and experimental observations
2. The aetiology of postoperative abdominal adhesions
3. The role of venous obstruction in the formation of intra-abdominal adhesions: An experimental study
4. Postoperative peritoneal adhesions. A study of the mechanisms
5. Metabolic response to severe injury
6. Priming of neutrophil oxidative responses by platelet-activating factor
7. Platelet-activating factor: Receptors and signal transduction
8. Effects of Y-24180, a receptor antagonist to platelet-activating factor, on allergic cutaneous eosinophilia in mice
9. Mast cell mediators and peritoneal adhesion formation in the rat
10. Lysophosphatidylcholine (LPC) induces proinflammatory cytokines by a platelet-activating factor (PAF) receptor-dependent mechanism
11. Randomized, double-blind phase II trial of Lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis
12. Roles of platelet-activating factor, interleukin-1beta and interleukin-6 in intestinal barrier dysfunction induced by mesenteric arterial ischemia and reperfusion
13. Phase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis
14. Inhibition of platelet-activating factor, intercellular adhesion molecule 1 and platelet endothelial cell adhesion molecule 1 reduces experimental pancreatitis-associated gut endothelial barrier dysfunction
15. Effect of a platelet-activating factor antagonist on pancreatitis-associated gut barrier dysfunction in rats
16. Role of proteolytic enzyme in the prevention of postoperative intraperitoneal adhesions
17. A simplified method for the analysis of hydroxyproline in biological tissues
18. The role of neutrophils in the formation of peritoneal adhesions
19. The operative aetiology and types of adhesions causing small bowel obstruction
20. The effect of medroxyprogesterone acetate and heparin in the prevention of postsurgical adhesion formation in the rat uterine model
21. The role of plasminogen activator in adhesion prevention
22. Adhesions: Preventive strategies
23. Failure of intraperitoneal adjuncts to improve the outcome of pelvic operations in young women
24. Reduction of surgery-induced peritoneal adhesions by methylene blue
25. Prevention of peritoneal adhesions in rats with trimetazidine
26. Preoperative administration of antibodies against tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 (IL-1) and their impact on peritoneal adhesion formation
27. Effects of interleukin-6 and its neutralizing antibodies on peritoneal adhesion formation and wound healing
28. The effect of monocyte chemotactic protein 1 in intraperitoneal adhesion formation in a mouse model
29. Modulation of neutrophil oxidative responses to soluble stimuli by platelet-activating factor
30. Endotoxin-induced migration of monocytes and PECAM-1 phosphorylation are abrogated by PAF receptor antagonists
31. Hypoxia induces PECAM-1 phosphorylation and transendothelial migration of monocytes
32. The use of lexipafant in the treatment of acute pancreatitis
33. Lexipafant (BB-882), a platelet activating factor receptor antagonist, ameliorates mucosal inflammation in an animal model of colitis
34. The scientific basis of medical therapy of acute pancreatitis. Could it work, and is there a role for lexipafant?
35. Lung injury in the microembolic model of acute pancreatitis and amelioration by lexipafant (BB-882), a platelet-activating factor antagonist
36. Prospective placebo-controlled randomized trial of lexipafant in predicted severe acute pancreatitis
37. Effect of a platelet-activating factor antagonist, WEB 2086, on inhibition of active oxygen generation in human polymorphonuclear leukocytes
38. Binding of [3H]SR 27417, a novel platelet-activating factor (PAF) receptor antagonist, to rabbit and human platelets and polymorphonuclear leukocytes
39. Platelet-activating factor antagonist TCV-309 attenuates the induction of the cytokine network in experimental endotoxemia in chimpanzees
40. Role of platelet-activating factor in pancreatitis-associated acute lung injury in the rat
41. Platelet-activating factor and platelet-activating factor antagonists in acute pancreatitis
42. Interleukin-6 in the injured patient: Marker of injury or mediator of inflammation?
43. Increased plasma levels of interleukin-6 in sepsis
44. The inflammatory profile of interleukin-6, interleukin-8, and soluble cell adhesion molecule-1 in postinjury multiple organ failure
45. Elevated interleukin-6 levels in peritoneal fluid of patients with pelvic pathology
46. IL-6: Insights into novel biological activities
47. Interleukin-6 stimulates neutrophil production of platelet-activating factor
48. IL-1beta and IL-6 stimulate the production of platelet-activating factor by cultured rabbit synovial cells